Profile data is unavailable for this security.
About the company
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
- Revenue in USD (TTM)241.52m
- Net income in USD52.37m
- Incorporated2017
- Employees229.00
- LocationKrystal Biotech Inc2100 Wharton St Ste 701PITTSBURGH 15203-1973United StatesUSA
- Phone+1 (412) 586-5830
- Fax+1 (302) 655-5049
- Websitehttps://www.krystalbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals Inc | 112.53m | -261.57m | 3.63bn | 226.00 | -- | 323.37 | -- | 32.24 | -4.31 | -4.31 | 1.86 | 2.49 | 0.3136 | 1.18 | 6.65 | 497,920.30 | -72.15 | -47.21 | -90.85 | -52.84 | 88.61 | -- | -230.11 | -681.38 | 3.34 | -- | 0.417 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Alvotech SA | 393.92m | -441.45m | 3.75bn | 999.00 | -- | -- | -- | 9.52 | -1.90 | -1.90 | 1.56 | -1.29 | 0.3595 | 1.56 | 4.24 | 394,313.30 | -40.28 | -- | -47.87 | -- | 59.03 | -- | -112.07 | -- | 1.92 | -0.0519 | 1.41 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Immunovant Inc | 0.00 | -323.01m | 3.90bn | 207.00 | -- | 8.66 | -- | -- | -2.21 | -2.21 | 0.00 | 3.06 | 0.00 | -- | -- | 0.00 | -79.97 | -- | -92.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Ultragenyx Pharmaceutical Inc | 522.75m | -558.99m | 4.25bn | 1.28k | -- | 12.25 | -- | 8.13 | -6.46 | -6.46 | 6.02 | 3.76 | 0.3766 | 1.91 | 6.06 | 409,674.80 | -40.27 | -33.35 | -50.12 | -38.30 | 86.25 | 93.13 | -106.93 | -154.71 | 2.65 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Biohaven Ltd | 0.00 | -804.34m | 4.45bn | 239.00 | -- | 13.57 | -- | -- | -9.35 | -9.35 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -180.09 | -- | -236.99 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Alkermes Plc | 1.51bn | 502.58m | 4.48bn | 2.10k | 9.39 | 3.47 | 8.26 | 2.98 | 2.95 | 1.96 | 8.83 | 7.99 | 0.6788 | 1.32 | 4.24 | 716,724.30 | 22.67 | 1.34 | 28.90 | 1.74 | 83.17 | 83.32 | 33.39 | 2.12 | 3.03 | -- | 0.1827 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Arcellx Inc | 155.82m | -40.42m | 4.72bn | 130.00 | -- | 9.75 | -- | 30.27 | -0.7196 | -0.7196 | 2.98 | 8.95 | 0.226 | -- | -- | 1,198,600.00 | -5.86 | -38.82 | -7.56 | -45.41 | -- | -- | -25.94 | -339.38 | -- | -- | 0.022 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Crinetics Pharmaceuticals Inc | 1.04m | -277.91m | 5.09bn | 290.00 | -- | 5.53 | -- | 4,902.86 | -3.72 | -3.72 | 0.0139 | 10.30 | 0.0013 | -- | 0.1222 | 3,582.76 | -34.61 | -42.53 | -36.80 | -45.36 | -- | -- | -26,298.27 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Krystal Biotech Inc | 241.52m | 52.37m | 5.24bn | 229.00 | 103.14 | 5.92 | 88.24 | 21.71 | 1.77 | 1.77 | 8.21 | 30.80 | 0.2725 | 1.51 | 4.53 | 1,054,664.00 | 5.91 | -11.50 | 6.33 | -12.01 | 92.55 | -- | 21.68 | -492.85 | 7.76 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Ionis Pharmaceuticals Inc | 803.07m | -358.81m | 5.36bn | 927.00 | -- | 8.09 | -- | 6.67 | -2.45 | -2.45 | 5.50 | 4.20 | 0.267 | 0.3864 | 10.02 | 866,306.40 | -11.93 | -6.30 | -13.52 | -7.44 | 98.70 | 98.75 | -44.68 | -21.23 | 8.82 | -- | 0.6587 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| TG Therapeutics Inc | 264.79m | -14.36m | 5.38bn | 319.00 | -- | 28.01 | -- | 20.31 | -0.1067 | -0.1067 | 1.74 | 1.23 | 0.5775 | 0.5234 | 3.42 | 1,002,992.00 | -3.13 | -62.87 | -3.91 | -80.06 | 88.32 | -- | -5.42 | -405.03 | 3.91 | 0.2097 | 0.5596 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Cytokinetics, Inc. | 3.22m | -576.40m | 5.63bn | 423.00 | -- | -- | -- | 1,747.67 | -5.39 | -5.39 | 0.0301 | -0.118 | 0.003 | -- | 2.35 | 7,609.93 | -52.96 | -43.14 | -57.95 | -47.22 | -- | -- | -17,906.24 | -540.47 | -- | -14.27 | 1.02 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Viking Therapeutics Inc | 0.00 | -99.15m | 5.75bn | 33.00 | -- | 6.31 | -- | -- | -0.937 | -0.937 | 0.00 | 8.18 | 0.00 | -- | -- | 0.00 | -15.02 | -21.91 | -15.47 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Nuvalent Inc | 0.00 | -224.29m | 6.05bn | 127.00 | -- | 5.87 | -- | -- | -3.48 | -3.48 | 0.00 | 15.81 | 0.00 | -- | -- | 0.00 | -27.79 | -- | -29.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Blueprint Medicines Corp | 434.41m | -128.05m | 6.14bn | 638.00 | -- | 19.58 | -- | 14.13 | -2.11 | -2.11 | 6.92 | 4.93 | 0.3769 | 0.8954 | 8.11 | 663,227.50 | -11.11 | -29.92 | -13.84 | -34.06 | 97.01 | -- | -29.48 | -116.65 | 3.27 | -10.80 | 0.5525 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Data as of Nov 22 2024. Currency figures normalised to Krystal Biotech Inc's reporting currency: US Dollar USD
63.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 4.29m | 14.92% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.71m | 12.93% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.78m | 9.68% |
| Avoro Capital Advisor LLCas of 30 Sep 2024 | 2.62m | 9.13% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.45m | 5.06% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 879.08k | 3.06% |
| Redmile Group LLCas of 30 Sep 2024 | 810.25k | 2.82% |
| Geode Capital Management LLCas of 30 Sep 2024 | 591.63k | 2.06% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 569.38k | 1.98% |
| Hood River Capital Management LLCas of 30 Sep 2024 | 502.10k | 1.75% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
